Patents by Inventor Michael Klass
Michael Klass has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170108503Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: December 29, 2016Publication date: April 20, 2017Inventors: Michael KLASS, Christine KUSLICH, George POSTE
-
Patent number: 9469876Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.Type: GrantFiled: April 6, 2011Date of Patent: October 18, 2016Assignee: Caris Life Sciences Switzerland Holdings GmbHInventors: George Poste, Michael Klass, David Spetzler, Traci Pawlowski
-
Patent number: 9128101Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.Type: GrantFiled: March 1, 2011Date of Patent: September 8, 2015Assignee: Caris Life Sciences Switzerland Holdings GmbHInventors: David D. Halbert, George Poste, Michael Klass, David Spetzler, Traci Pawlowski, Daniel Holterman
-
Publication number: 20150024961Abstract: Biomarkers such as exosomes and/or RNA, e.g., microRNA, can be used for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Such biomarkers can be used in profiling of physiological states or determining phenotypes. Biomarkers can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Biomarkers can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: July 28, 2014Publication date: January 22, 2015Inventors: Michael KLASS, Christine KUSLICH, George POSTE
-
Publication number: 20140162888Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.Type: ApplicationFiled: April 6, 2011Publication date: June 12, 2014Inventors: Christine Kuslich, George Poste, Michael Klass, David Spetzler, Traci Pawlowski
-
Publication number: 20130203061Abstract: Provided herein are methods and systems for isolating, storing, and analyzing a vesicle from a sample The vesicle can be isolated using one or more lectins that bind to a vesicle One or more additional binding agents, such as a non lectin binding agent can also be used to isolate or analyze a vesicleType: ApplicationFiled: November 30, 2010Publication date: August 8, 2013Inventors: Michael Klass, David Spetzler, Traci Pawlowski
-
Publication number: 20130184169Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: ApplicationFiled: April 27, 2012Publication date: July 18, 2013Applicant: Caris Life Sciences Luxembourg Holdings a Luxembourg corporationInventors: Michael KLASS, George POSTE
-
Publication number: 20130178383Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.Type: ApplicationFiled: August 29, 2012Publication date: July 11, 2013Inventors: David SPETZLER, Traci PAWLOWSKI, Michael KLASS, George POSTE
-
Publication number: 20130045882Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: ApplicationFiled: July 6, 2012Publication date: February 21, 2013Inventors: Michael KLASS, Christine KUSLICH, George POSTE
-
Publication number: 20130005599Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: July 6, 2012Publication date: January 3, 2013Applicants: Caris Life Sciences Luxembourg HoldingsInventors: Michael KLASS, Christine KUSLICH, George POSTE
-
Patent number: 8278059Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: GrantFiled: January 19, 2011Date of Patent: October 2, 2012Assignee: Caris Life Sciences Luxembourg Holdings, S.A.R.L.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Patent number: 8211653Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: GrantFiled: January 19, 2011Date of Patent: July 3, 2012Assignee: Caris Life Sciences Luxembourg Holdings, S.A.R.L.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Patent number: 8192954Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: GrantFiled: December 8, 2010Date of Patent: June 5, 2012Assignee: Caris Life Sciences Luxembourg Holdings, S.A.R.L.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Publication number: 20110159506Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: ApplicationFiled: December 8, 2010Publication date: June 30, 2011Applicant: CARIS LIFE SCIENCES LUXEMBOURG HOLDINGSInventors: MICHAEL KLASS, CHRISTINE KUSTILICH, GEORGE POSTE
-
Publication number: 20110151460Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: January 19, 2011Publication date: June 23, 2011Inventors: Michael Klass, Christine Kuslich, George Poste
-
Patent number: 7897356Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: GrantFiled: November 12, 2009Date of Patent: March 1, 2011Assignee: Caris Life SciencesInventors: Michael Klass, Christine Kuslich, George Poste
-
Patent number: 7888035Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: GrantFiled: October 30, 2009Date of Patent: February 15, 2011Assignee: Caris MPI, Inc.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Publication number: 20100203529Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: February 5, 2010Publication date: August 12, 2010Applicant: Caris MPI, Inc.Inventors: Christine Kuslich, George Poste, Michael Klass
-
Publication number: 20100184046Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.Type: ApplicationFiled: November 12, 2009Publication date: July 22, 2010Applicant: Caris MPI, Inc.Inventors: Michael Klass, Christine Kuslich, George Poste
-
Publication number: 20100113290Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.Type: ApplicationFiled: October 30, 2009Publication date: May 6, 2010Applicant: Caris MPI, Inc.Inventors: Michael KLASS, Christine Kuslich, George Poste